Joanna A. Cooper

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Factors that influence adherence with disease-modifying therapy in MS

Katherine Treadaway, Gary Cutter, Amber Salter et al. · Journal of Neurology · 2009 · 257 citations

Pharmacy, Pharmacotherapy, Self-management Support +11

Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses

Roy W. Beck, Danielle L. Chandler, Stephen R. Cole et al. · Annals of Neurology · 2002 · 130 citations

Life Sciences, Neurology, Pharmacotherapy +13

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 104 citations · Full text

Life Sciences, Neurology, Neuroscience +9

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Gavin Giovannoni, Jeffrey Cohen, Alasdair Coles et al. · Neurology · 2016 · 62 citations · Full text

Medicine, Neurology, Pharmacotherapy +13